perifosine has been researched along with Colorectal Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Chen, J; Chen, MB; Liu, CY; Lu, PH; Tao, GQ; Wang, LQ; Wu, XY | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
1 trial(s) available for perifosine and Colorectal Cancer
| Article | Year |
|---|---|
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
2 other study(ies) available for perifosine and Colorectal Cancer
| Article | Year |
|---|---|
Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caco-2 Cells; Cell Death; Cell Line, Tumor; Cell Proliferation; Ceramides; Colorectal Neoplasms; Curcumin; Cyclin D1; Down-Regulation; Drug Synergism; Endoplasmic Reticulum; Female; HCT116 Cells; HT29 Cells; Humans; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Multiprotein Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Phosphorylcholine; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |